©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 28, 2016; 8(21): 874-880
Published online Jul 28, 2016. doi: 10.4254/wjh.v8.i21.874
Published online Jul 28, 2016. doi: 10.4254/wjh.v8.i21.874
Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria
Mohammed Elshamy, Federico Aucejo, Bijan Eghtesad, Hepato-biliary and Transplant Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
KV Narayanan Menon, Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Author contributions: This manuscript was written completely by the stated authors.
Conflict-of-interest statement: None.
Correspondence to: Bijan Eghtesad, MD, Hepato-biliary and Transplant Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue/A100, Cleveland, OH 44195, United States. eghtesb@ccf.org
Telephone: +1-216-4445914 Fax: +1-216-4449375
Received: March 30, 2016
Peer-review started: April 6, 2016
First decision: June 7, 2016
Revised: June 17, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: July 28, 2016
Processing time: 113 Days and 11.9 Hours
Peer-review started: April 6, 2016
First decision: June 7, 2016
Revised: June 17, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: July 28, 2016
Processing time: 113 Days and 11.9 Hours
Core Tip
Core tip: Numerous expanded selection criteria for hepatocellular carcinoma (HCC)-liver transplantation (LT) have been proposed worldwide. Surrogates of favorable tumor biology such as Post-locoregional therapy strategies which observe tumor behavior, and the addition of HCC biomarkers to selection criteria have been explored. Further investigation is encouraged to identify patients beyond MC with the most favorable tumor biology for LT.